Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2005-05-16
2010-10-12
Kishore, Gollamudi S (Department: 1612)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
Reexamination Certificate
active
07811602
ABSTRACT:
The present invention includes novel liposomes comprising dihydrosphingomyelin. The invention also includes compositions comprising these liposomes and a therapeutic agent, in addition to methods and kits for delivering a therapeutic agent or treating a disease, e.g., a cancer, using these compositions.
REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4217344 (1980-08-01), Vanlerberghe et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4261975 (1981-04-01), Fullerton et al.
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4603044 (1986-07-01), Geho et al.
patent: 4737323 (1988-04-01), Martin et al.
patent: 4774085 (1988-09-01), Fidler
patent: 4837028 (1989-06-01), Allen
patent: 4857319 (1989-08-01), Crowe et al.
patent: 4880635 (1989-11-01), Janoff et al.
patent: 4885172 (1989-12-01), Bally et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 4957773 (1990-09-01), Spencer et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5171578 (1992-12-01), Bally et al.
patent: 5376380 (1994-12-01), Kikuchi et al.
patent: 5534499 (1996-07-01), Ansell
patent: 5543152 (1996-08-01), Webb et al.
patent: 5578320 (1996-11-01), Janoff et al.
patent: 5736155 (1998-04-01), Bally et al.
patent: 5741516 (1998-04-01), Webb et al.
patent: 5814335 (1998-09-01), Webb et al.
patent: 5817334 (1998-10-01), Schmidt et al.
patent: 5820873 (1998-10-01), Choi et al.
patent: 5837279 (1998-11-01), Janoff et al.
patent: 5837282 (1998-11-01), Fenske et al.
patent: 5858398 (1999-01-01), Cho
patent: 5885613 (1999-03-01), Holland et al.
patent: 5922350 (1999-07-01), Janoff et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981564 (1999-11-01), Pagé et al.
patent: 6320017 (2001-11-01), Ansell
patent: 6355267 (2002-03-01), Collins
patent: 6380405 (2002-04-01), Ekwuribe et al.
patent: 6475517 (2002-11-01), Tagawa et al.
patent: 6610835 (2003-08-01), Liotta et al.
patent: 2002/0041897 (2002-04-01), Dang
patent: 2002/0110586 (2002-08-01), Madden et al.
patent: 2002/0119990 (2002-08-01), Madden et al.
patent: 2004/0071768 (2004-04-01), Sarris et al.
patent: 2004/0228909 (2004-11-01), Sarris et al.
patent: WO 91/17424 (1991-11-01), None
patent: WO 95/08986 (1995-04-01), None
patent: WO 02/072010 (2002-09-01), None
Abra, R., et al., “The Next Generation of Liposome Delivery Systems: Recent Experience with Tumor-targeted, Sterically-stabilized Immunoliposomes and Active-loading Gradients,”J Liposome Res., 12(1-2):1-3, Feb.-May 2002.
Allen, T., et al., “Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System,”FEBS Lett., 223(1):42-6, Oct. 19, 1987.
Allen, T., et al., “Liposomes Containing Synthetic Lipid Derivatives of Poly(ethylene glycol) Show Prolonged Circulation Half-lives in Vivo,”Biochim Biophys Acta., 1066(1):29-36, Jul. 1, 1991.
Allen, T., et al., “A New Strategy for Attachment of Antibodies to Sterically Stabilized Liposomes Resulting in Efficient Targeting to Cancer Cells,”Biochim Biophys Acta., 1237(2):99-108, Jul. 26, 1995.
Allen, T., et al.,Liposomes, Janoff, A.S. (ed.), Marcel Dekker Inc., New York, 1999, Ch. 3, “Liposome Pharmacokinetics—Classical, Sterically Stabilized, Cationic Liposomes and Immunoliposomes,” pp. 63-87.
Bangham, A.., et al., “Ultrastructure of Membranes: Biomolecular Organization,”Br Med Bull., 24(2):124-6, May 1968.
Bangham, A.., “Membrane Models with Phospholipids,”Prog Biophys Mol Biol., 18:29-95, 1968.
Barenholz, Y., et al., “A Calorimetric Study of the Thermotropic Behavior of Aqueous Dispersions of Natural and Synthetic Sphingomyelins,”Biochemistry., 15(11):2441-7, Jun. 1, 1976.
Barenholz, Y., et al.,In Physiology of Membrane Fluidity, vol. 1, Shinitsky, M. (ed.), CRC Press, Boaca Raton, FL, Ch. 5, “Sphingomyelin-Lecithin Balance in Membranes: Compositions, Structure, and Function Relationships,” pp. 131-174.
Bloomfield, V., “Quasi-Elastic Light Scattering Applications in Biochemistry and Biology,”Ann. Rev. Biophys. Bioeng.10:421-450, 1981.
Blume, G., et al., “Specific Targeting with Poly(ethylene glycol)-modified Liposomes: Coupling of Homing Devices to the Ends of the Polymeric Chains Combines Effective Target Binding with Long Circulation times,”Biochim Biophys Acta., 1149(1):180-4, Jun. 18, 1993.
Boman, L., et al., “Liposomal Vincristine which Exhibits Increased Drug Retention and Increased Circulation Longevity Cures Mice Bearing P388 Tumors,”Cancer Res., 54(11):2830-3, Jun. 1, 1994.
Byrdwell, W., et al., “Liquid Chromatography/mass-spectrometric Characterization of Sphingomyelin and Dihydrosphingomyelin of Human Lens Membranes,”Ophthalmic Res., 29(4):191-206, 1997.
Chu, E., et al.,Physician's Cancer Chemotherapy Drug Manual, Jones and Bartlett Publishers, Massachusetts, 2002, Ch. 4, “Common Chemotherapy Regimens in Clinical Practice,” pp. 387-461.
Deamer, D. et al., “Large Volume Liposomes by an Ether Vaporization Method,”Biochim. et Biophys. Acta443:629-634, 1976.
DeFrees, S., et al., “Sialyl Lewis x-Liposomes as a Multivalent Ligand and Inhibitor of E-Selection Mediated Cellular Adhesion,”J. Am. Chem. Soc., 118:6101-6104, 1996.
U.S. Appl. No. 08/316,394, filed Sep. 30, 1994, Ansell.
U.S. Appl. No. 08/996,783, filed Dec. 23, 1997, Ansell.
Deutsch, H., et al., “Synthesis of Congeners and Prodrugs. 3. Water-soluble Prodrugs of Taxol with Potent Antitumor Activity,”J Med Chem., 32(4):788-92, Apr. 1989.
Dumontet, C. et al., “Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death,”J. Clin. Oncol.17(3):1061-1070, Mar. 1999.
Fenske, D., et al., “Ionophore-mediated Uptake of Ciprofloxacin and Vincristine into Large Unilamellar Vesicles Exhibiting Transmembrane Ion Gradients,”Biochim Biophys Acta., 1414(1-2):188-204, Nov. 11, 1998.
Fiebig, H., et al.,Tumor Models in Cancer Research, Teicher, B.A.(ed.), Humana Press Inc. Totowa, 2002, Ch. 7, “Human Tumor Xenografts and Explants,” pp. 113-137.
Fraley, R., et al., “Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Potential for Gene Transfer,”Proc Natl Acad Sci U S A., 76(7):3348-52, Jul. 1979.
Gruner, S., chapter 1 “Materials Properties of Liposomal Bilayers,” in Ostro, M.J. (ed.),Liposomes: From Biophysics to Therapeutics, Marcel Dekker, New York, 1993, pp. 1-38.
Heath, T., “Covalent Attachment of Proteins to Liposomes,”Methods in Enzymology149:111-119, 1987.
Hope, M. et al., “Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure. Characterization of Size Distribution, Trapped Volume and Ability to Maintain a Membrane Potential,”Biochim. et Biophys. Acta812:55-65, 1985.
Hope, M. et al., “Generation of Multilamellar and Unilamellar Phospholipid Vesicles,”Chemistry and Physics of Lipids40:89-107, 1986.
Karlsson, A., et al., “Molecular Species of Sphingomyelin: Determination by High-Performance Liquid Chromatography/mass Spectrometry with Electrospray and High-Performance Liquid Chromatography/tandem Mass Spectrometry with Atmospheric Pressure Chemical Ionization,”J Mass Spectrom., 33(12):1192-8, Dec. 1998.
King, R.E.,Remington's Pharmaceutical Sciences, 17thEd., Mack Publishing Co., Philadelphia, PA, 1985, Part 8, “Pharmaceutical Preparations and Their Manufacture,” pp. 1409-1677.
Kirpotin, D., et al., “Liposomes with Detachable Polymer Coating: Destabilization and Fusion of Dioleoylphosphatidylethanolamine Vesicles Triggered by Cleavage of Surface-Grafted Poly(ethylene glycol),”FEBS Lett., 388(2-3):115-8, Jun. 17, 1996.
Klibanov, A., et al., “Long-Circulating Liposomes: Development and Perspective
Ansell Steven M
Cullis Pieter R
Hope Michael J
Madden Thomas D
Maurer Norbert
Kishore Gollamudi S
Seed IP Law Group PLLC
Tekmira Pharmaceuticals Corporation
LandOfFree
Liposomal formulations comprising dihydrosphingomyelin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal formulations comprising dihydrosphingomyelin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal formulations comprising dihydrosphingomyelin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242207